Navigation Links
Adis Journals Make Impressive Impact Factor Gains
Date:7/18/2011

YARDLEY, Pa., July 18, 2011 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced strong impact factor (IF) gains for its Adis line of drug therapy and patient management journals.  11 of the 13 Adis journals that carried IFs in 2009 bettered their performance in 2010 according to the annual Journal Citation Reports® published in June.The most impressive gains over 2009 were made by PharmacoEconomics (IF 3.44) – up 34 percent to become the leading Health Outcomes Research journal, and Sports Medicine (IF 5.072) - up 63 percent, also becoming the highest ranking title in its field.

Drugs in R&D (IF 1.707), re-launched in 2010 as Adis' first fully open access MEDLINE-indexed journal gained 26 percent. Other standout performers include CNS Drugs (IF 4.497) - up 16 percent and Biodrugs (IF 4.192) – up 20 percent.  

"The price of Adis journals was significantly restructured at the end of 2009 providing affordable access for a wider group of customers," said Iain Spray, Adis Product Manager, Wolters Kluwer Pharma Solutions.  "These IF gains are partly the result of that increased access, and the continued determination of our editors, editorial boards and publishing team to strive for the highest level of quality."

An impact factor quantifies the relative influence of a scholarly journal in its scientific field.  It is a measure of the frequency with which the average article in a journal has been cited in a given year.

For more than 40 years, medical and scientific researchers have turned to Adis for its high quality, peer-reviewed content. Adis journals, covering the evidence-based pharmacology spectrum from clinical pharmacology to drug development and drug safety, to pharmacoeconomics, medical biotechnology and disease management, are available on AdisOnline (http://adisonline.com).  

For more information, visit the company's website at www.wolterskluwerpharma.com.

About Wolters Kluwer Pharma SolutionsWolters Kluwer Pharma Solutions, Inc. (Phoenix, AZ and Yardley, PA) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, Source® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes 19 peer-reviewed drug research journals and 2 newsletters and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.

The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2010 annual revenues of euro 3.6 billion ($4.7 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.Contact:

Tom KivettKivett & Company Communications+1 212 727-2935tkivett@kivettandco.com
'/>"/>

SOURCE Wolters Kluwer Pharma Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adis Journals Embrace Open Access
2. Reprints Desk Bolsters Ultra-Rapid Document Delivery Service Through New Electronic Sourcing Agreement with the American Medical Association, Publisher of JAMA & Archives Journals
3. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
4. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
9. ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
10. Update on IMPACT Study Results
11. Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid ... Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog and ... NOT the only solution to deal with thyroid disease. , Dr. Wentz completed ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System ... the iSAFE Plus. These iSAFE products are the most affordable and most advanced medical ... Plus offer direct GPS Location and two-way calling with the push of a button ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board Certified ... Integrative Medicine and available for application on Saturday, May 27, 2017, following Thursday, ... Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities ...
Breaking Medicine News(10 mins):